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DNA methylation plays an important role in suppressing retrotransposon activity in mammalian genomes, yet
there are stages of mammalian development where global hypomethylation puts the genome at risk of retro-
transposition-mediated genetic instability. Hypomethylated primordial germ cells appear to limit this risk by
expressing a cohort of retrotransposon-suppressing genome-defence genes whose silencing depends on
promoter DNA methylation. Here, we investigate whether similar mechanisms operate in hypomethylated
trophectoderm-derived components of the mammalian placenta to couple expression of genome-defence
genes to the potential for retrotransposon activity. We show that the hypomethylated state of the mouse pla-
centa results in activation of only one of the hypomethylation-sensitive germline genome-defence genes:
Tex19.1. Tex19.1 appears to play an important role in placenta function as Tex19.12/2 mouse embryos exhibit
intra-uterine growth retardation and have small placentas due to a reduction in the number of spongiotropho-
blast, glycogen trophoblast and sinusoidal trophoblast giant cells. Furthermore, we show that retrotrans-
poson mRNAs are derepressed in Tex19.12/2 placentas and that protein encoded by the LINE-1
retrotransposon is upregulated in hypomethylated trophectoderm-derived cells that normally express
Tex19.1. This study suggests that post-transcriptional genome-defence mechanisms are operating in the pla-
centa to protect the hypomethylated cells in this tissue from retrotransposons and suggests that imbalances
between retrotransposon activity and genome-defence mechanisms could contribute to placenta dysfunction
and disease.
INTRODUCTION
Retrotransposons are mobile genetic elements that amplify and
integrate into new genomic locations through RNA intermedi-
ates. These parasitic DNA sequences are highly abundant in
mammalian DNA and typically account for 40–70% of
sequenced mammalian genomes (1–4). To limit the activity
of these elements, mammals possess numerous genome-
defence mechanisms that can suppress retrotransposon activity
at transcriptional and post-transcriptional levels in different
cell types (5–7). DNA methylation, histone modification and
polycomb-mediated repression have all been implicated in
transcriptional repression of retrotransposons in mouse embry-
onic stem (ES) cells (8–10). DNA methylation also appears to
play an important role in repressing retrotransposons in differ-
entiated embryonic tissue, particularly in the repression of
intracisternal A particle (IAP) retrotransposons (9,11,12).
Indeed, transcriptional repression of retrotransposons has
been proposed to be the primary function of DNA methylation
in mammalian genomes (13).
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At a genome-wide level, DNA methylation is high in most
differentiating embryonic tissues, with the notable exception
of the developing germline (14). Primordial germ cells
undergo extensive loss of DNA methylation during their de-
velopment as part of a wider epigenetic reprogramming
event that resets imprints and other epigenetic marks
(15,16). However, global DNA hypomethylation has the po-
tential to induce retrotransposon activity and, therefore,
genome instability, in the developing germline (17). We
have previously shown that DNA hypomethylation in primor-
dial germ cells induces expression of a group of
hypomethylation-sensitive genome-defence genes (Tex19.1,
Piwil2, Mov10l1, Dazl and Asz1) that function to protect the
germline DNA from retrotransposon activity (17). Mutations
in Tex19.1, Piwil2, Mov10l1 or Asz1 result in derepression
of retrotransposons in testicular germ cells and male sterility
(18–22), whereas Dazl is required for efficient translation of
retrotransposon-suppressing genes Tex19.1 and Mvh (23,24).
The DNA methylation-dependent silencing of these genome-
defence genes appears to represent a developmental mechan-
ism that helps to suppress retrotransposon activity during
periods of global DNA hypomethylation and epigenetic repro-
gramming in the developing germline when the potential for
retrotransposon activation is high (17).
Like primordial germ cells, the placenta is globally hypo-
methylated relative to other mouse tissues, and the hypo-
methylated state of the placenta extends to retrotransposons
(14,25–27). Approximately, 40–50% of cytosines in a CpG
context are methylated within long terminal repeat (LTR),
long interspersed nuclear element (LINE) and short inter-
spersed nuclear element (SINE) classes of retrotransposon in
mouse placentas, compared with 75–80% in the embryo
(27). Specific types of retrotransposon, such as IAP and
LINE-1 elements, have also been shown to be hypomethylated
in the placenta relative to the embryo (25,28). The hypomethy-
lated epigenetic state of placental DNA could potentially gen-
erate a transcriptionally permissive environment for
retrotransposon expression (25), and numerous studies report
expression of retrotransposons in this tissue (reviewed in
29). However, it is not known whether mechanisms operate
in the placenta, as they do in the germline, to couple transcrip-
tional activation of hypomethylation-sensitive genome-
defence genes to the potential for retrotransposon activation
(17).
In this study, we show that the hypomethylated epigenetic
state of the placenta is associated with expression of specific
retrotransposons, but does not result in widespread activation
of retrotransposon expression in general. We find that only
one of the hypomethylation-sensitive germline genome-
defence genes, Tex19.1, is hypomethylated and expressed in
mouse placenta and that Tex19.12/2 embryos exhibit intra-
uterine growth retardation. Tex19.12/2 placentas are small
with thinner junctional zones and a reduced abundance of mul-
tiple trophectoderm-derived cell types when compared with
littermate controls. Microarray expression profiling of
Tex19.12/2 placentas shows that loss of Tex19.1 results in
increased expression of LINE-1 retrotransposons in this
tissue, and immunohistochemistry suggests that LINE-1 dere-
pression is occurring in the hypomethylated trophectoderm-
derived cell types that normally express Tex19.1. Our data
extend to the placenta the associations between DNA hypo-
methylation, Tex19.1 and post-transcriptional genome-defence
against retrotransposons that we have previously described in
the developing germline (17) and suggest that imbalances
between retrotransposon activity and host genome-defence
mechanisms might be associated with impaired placenta func-
tion in mammals.
RESULTS
Retrotransposon expression in the mouse placenta
DNA methylation is associated with transcriptional repression
of retrotransposons in embryos and embryo-derived cell lines
(9,11,12,30,31). Therefore, we investigated whether the hypo-
methylated state of the mouse placenta (25–27) permits wide-
spread retrotransposon expression in this tissue. We used our
recently developed microarray repeat-annotation methodology
(10) to extract information about placental expression of hun-
dreds of different types of retrotransposon from mouse
multiple-tissue gene expression data (32). Repeat annotation
of gene expression microarray data from E16 placentas and
E16 embryos from within this dataset showed that, in
general, retrotransposon classes (LTR, LINE and SINE) of
repeat probes appeared to be no more differentially expressed
between placenta and embryo than non-repeat probes (Fig. 1A
and B): although 51% of non-repeat probes are differentially
expressed (P , 0.01) between placenta and embryo, only
39% of retrotransposon probes are differentially expressed
(P , 0.01) between these tissues. Furthermore, similar
numbers of retrotransposon probes are upregulated and down-
regulated in the placenta [1850 retrotransposon probes signifi-
cantly (P , 0.01) upregulated, 1740 retrotransposon probes
significantly (P , 0.01) downregulated, x2-test P ¼ 0.2], sug-
gesting that the placenta is not any more permissive than em-
bryonic tissues for retrotransposon derepression, despite its
hypomethylated epigenetic state. Multiple families of LTR ret-
rotransposons (endogenous retroviruses) are reported to be
hypomethylated in placenta (40% DNA methylation) rela-
tive to the embryo (75% DNA methylation) (27). Although
LTR retrotransposons in general do not appear to be any more
differentially expressed between placenta and embryo than
non-repeat probes, we also investigated whether the five
LTR retrotransposons that are upregulated in mouse ES cells
in response to hypomethylation (9) might be specifically upre-
gulated in the placenta. Interestingly, this group of
methylation-sensitive LTR retrotransposons showed divergent
behaviour in the placenta, with expression of the IAPEz sub-
class of IAP elements increased relative to embryonic
tissues, MMERGLN and some RLTR1B elements decreased
and RLTR45 and some RLTR1B elements not changing
(Fig. 1C). Thus, there does not appear to be a strong correl-
ation between the retrotransposons upregulated in mouse ES
cells in response to DNA hypomethylation and retrotranspo-
sons expressed in the hypomethylated placenta.
IAP and LINE-1 elements are both strongly repressed by
DNA methylation in the developing germline (11,33) and
have each been shown to be hypomethylated in mouse pla-
centa (25,28). Therefore, we examined whether the hypo-
methylated status of these elements in the placenta would
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correlate with their increased expression in this tissue. Inter-
estingly, although LINE-1 elements do not show increased ex-
pression in the placenta, IAP elements (endogenous retrovirus
type K family of LTR retrotransposons) do (Fig. 1D and E).
Consistent with previous observations using hypomethylated
ES cells (9,10), some IAP probes were more strongly upregu-
lated than others in the hypomethylated placenta. The bulk
IAP probe population is upregulated around 2-fold in the pla-
centa; however, some groups of IAP probes are upregulated
more than 10-fold (Fig. 1E). Quantitative reverse
Figure 1. IAP retrotransposons are highly expressed in the placenta. (A–E) Repeat probe expression in gene expression microarray data from E16 placenta and
E16 embryo. Repetitive element probes are coloured as shown in the legend. n ¼ 3. (A and D) MA-plot showing the fold upregulation in the placenta versus the
average expression in the dataset for each probe. (B, C and E) Probability density function plots showing the relative likelihood that any individual probe is
upregulated by the indicated amount in the placenta. Dotted lines mark 2-fold changes in expression. (F) qRT-PCR analysis of IAP and LINE-1 retrotransposon
expression in placenta and embryo at E18.5. Error bars represent standard error, n ¼ 2, asterisks indicate P , 0.01 (t-test). (G) Immunohistochemistry (brown
precipitate) for IAP gag protein in E18.5 placenta. Sections were counterstained with haematoxylin, and non-specific IgG staining is shown as a negative control.
Approximate positions of the decidua basalis (db), junctional zone (Jz) and labyrinth (L) are indicated. Scale bar, 500 mm.
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transcription-polymerase chain reaction (qRT-PCR) for IAP
and LINE-1 expression in embryonic and placental tissue con-
firmed that IAP elements are upregulated in the placenta rela-
tive to the embryo, whereas LINE-1 elements are expressed at
a similar level in these tissues (Fig. 1F). Thus, expression of
IAP elements is associated with their hypomethylated state
in the placenta, but expression of LINE-1 elements is not.
The placenta contains cells derived from the mother, and from
the extraembryonic mesoderm and the trophectoderm of the
embryo, but only trophectoderm-derived cells are expected to
be hypomethylated (25,34,35). The trophectoderm-derived cells
contribute to the decidua basalis, junctional zone and labyrinth
layers of the mature placenta (34). To determine whether the
hypomethylated trophectoderm-derived cell types in the placenta
are responsible for the IAP expression in this tissue, we performed
immunohistochemistry for IAP gag protein. Anti-IAP gag immu-
nostaining showed that parietal trophoblast giant cells in the
decidua basalis, and spongiotrophoblast cells in the junctional
zone of the placenta, are expressing IAP (Fig. 1G). Low-level ex-
pression of IAPgag protein is also detectable in sinusoidal tropho-
blast giant cells in the labyrinth layer of the placenta (Fig. 1G).
The distribution of IAP gag-expressing cells in the placenta cor-
relates well with the distribution of trophectoderm-derived cells
(34). Thus, as proposed in the original study on DNA methylation
at repetitive sequences in extraembryonic tissues (25), the hypo-
methylated state of the placenta does appear to allow expression
of certain retrotransposons such as IAP. However, hypomethyla-
tion does not appear to cause widespread upregulation of retro-
transposon expression in general in this tissue. This suggests
that mechanisms other than DNA methylation are contributing
to transcriptional and/or post-transcriptional repression of
LINE-1 and other retrotransposons in the placenta.
DNA hypomethylation in the placenta is associated with
expression of the hypomethylation-sensitive
genome-defence gene Tex19.1
We have recently shown that expression of a cohort of germ-
line genome-defence genes is activated by DNA hypomethyla-
tion in primordial germ cells as part of a mechanism that can
protect germline DNA from the mutagenic activity of retro-
transposons (17). The hypomethylated epigenetic state of pla-
cental DNA affects gene promoters in addition to
retrotransposons (27); therefore, we investigated whether this
cohort of hypomethylation-sensitive germline genome-
defence genes is also expressed in the hypomethylated pla-
centa. Tex19.1 has been previously reported to be expressed
in extraembryonic tissues (17,36), but analysis of multiple-
tissue microarray data (32) suggests that no other known
member of this group of genome-defence genes is expressed
in the placenta (Fig. 2A). We verified by qRT-PCR that
Tex19.1 is the only known hypomethylation-sensitive germ-
line genome-defence gene highly expressed in the placenta
(Fig. 2B). The differential expression of the germline genome-
defence genes in the placenta suggests that Tex19.1 may be
functioning independently of the remaining germline genome-
defence genes in this tissue.
We next tested whether the differential expression of the
genome-defence genes reflects differences in promoter
DNA methylation. Bisulphite sequencing of placental and
embryonic DNA showed that Tex19.1 is more extensively
hypomethylated in placental DNA than the other germline
genome-defence genes (Fig. 2C). Interestingly, individual
clones in the Tex19.1 bisulphite sequencing data were either
highly methylated or unmethylated suggesting that two epi-
genetically distinct populations of Tex19.1 DNA molecules
are present in the placenta. Furthermore, the proportion of
hypomethylated Tex19.1 clones (60%) correlates reasonably
well with the contribution of hypomethylated trophectoderm-
derived cells in mid-gestation placentas (35). In contrast to
Tex19.1, Dazl is highly methylated in both placenta and
embryo, and although there is a small drop in methylation
levels at Mov10l1 and Asz1 promoters in the placenta relative
to the embryo, these genes are each highly methylated in both
tissues (Fig. 2C). A small number of highly hypomethylated
Asz1 clones are present in the placenta samples (Fig. 2C),
which could reflect some Asz1 expression in a small propor-
tion of cells in the placenta (Fig. 2B). Piwil2 is not as
highly methylated as any of the other genome defence genes
in the embryo and also appears to be less methylated in the
placenta (Fig. 2C). However, the placental hypomethylation
of Piwil2 is not as extensive as Tex19.1. The absence of
robust Piwil2 expression in the placenta (Fig. 2A and B)
could reflect the activity of the residual 40% methylation
at this promoter, or the DNA methylation-independent compo-
nent of Piwil2 repression that is evident upon differentiation of
Dnmt3a2/2 Dnmt3b2/2 ES cells (17). Regardless, with the
exception of Tex19.1, the germline genome-defence genes
do not appear to be as sensitive to placental DNA hypomethy-
lation as they are to the DNA hypomethylation event that
occurs in the developing germline (17). Thus, any methyla-
tion-sensitive feedback loop to protect the placenta from retro-
transposons either involves only Tex19.1 or a completely
different set of genes altogether.
Dazl has been reported to be required for efficient transla-
tion of Tex19.1 mRNA in germ cells (24); therefore, the
absence of Dazl expression in the placenta (Fig. 2A and B)
could impair TEX19.1 protein expression, despite the presence
of Tex19.1 mRNA in this tissue. Anti-TEX19.1 immunohisto-
chemistry in E18.5 (Fig. 2D) and E9.5 (Supplementary Mater-
ial, Fig. S1) placentas suggests that TEX19.1 protein is present
in the placenta, despite the absence of Dazl expression. The
anti-TEX19.1 immunostaining appears to be specific as it is
not present in Tex19.12/2 placentas (Fig. 2D). In wild-type
embryos, anti-TEX19.1 immunostaining is present in tropho-
blast cells in each of the decidua basalis, junctional zone
and labyrinth layers of the placenta, but was not detected in
the endothelial cells or the chorionic plate (Fig. 2D). This sug-
gests that Tex19.1 is expressed in the hypomethylated
trophectoderm-derived components of the placenta, but not
in methylated extraembryonic mesoderm-derived components
(25,34) and is consistent with mRNA in situ hybridization data
(36). There is also considerable overlap between IAP expres-
sion (Fig. 1G) and TEX19.1 expression (Fig. 2D) with parietal
trophoblast giant cells, spongiotrophoblasts and sinusoidal
trophoblast giant cells expressing both of these proteins.
Taken together, these data suggest that Tex19.1 is the only
hypomethylation-sensitive germline genome-defence gene
that is hypomethylated and expressed in the placenta.
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Figure 2. Tex19.1 is the only known germline genome-defence gene that is hypomethylated and expressed in the placenta. (A) Microarray expression data
showing expression of the hypomethylation-sensitive genome-defence genes in E16 placenta and adult testis relative to E16 embryo for each gene. Error
bars indicate standard error. n ¼ 3. (B) qRT-PCR for expression of the hypomethylation-sensitive genome-defence genes in E18.5 placenta and embryo relative
to adult testis. Error bars indicate standard error. n ¼ 2. (C) Bisulphite sequencing of the promoters of the hypomethylation-sensitive genome-defence genes in
two independent placental and embryonic DNA samples. Each line represents a sequenced clone, filled circles represent methylated CpGs and open circles rep-
resent unmethylated CpGs. The percentage of total methylation in each sample is indicated. (D) Immunohistochemistry (brown precipitate) with anti-TEX19.1
antibody on wild-type and Tex19.12/2 E18.5 placenta. Sections were counterstained with haematoxylin. Approximate positions of the decidua basalis (db), junc-
tional zone (Jz) and labyrinth (L) are indicated. Scale bar, 500 mm.
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Tex19.1 might therefore play an important role in suppressing
retrotransposon activity in this tissue.
Tex19.1 is required for normal placental development
We next investigated if Tex19.1 expression has any functional
consequences for placental development. Defects in placental
function would be expected to manifest as embryonic lethality
and/or reduced embryo weight, depending on the severity of
the defect. Tex19.12/2 embryos have been reported to be
born at a sub-Mendelian frequency from heterozygous
crosses (19,37), with lethality affecting females more strongly
than males (37). The reduced viability of Tex19.12/2 embryos
could reflect a function for Tex19.1 in the placenta, or in pluri-
potent cells, where it is also expressed. In contrast to previous-
ly published data (37), although loss of Tex19.1 was associated
with embryonic lethality, this lethality did not appear to affect
females more strongly than males, despite our analysis includ-
ing almost 1000 genotyped pups (Supplementary Material,
Table S1). However, we noticed that the requirement for
Tex19.1 during embryonic development was much stronger
when mothers are lactating and nursing a pre-existing litter
during pregnancy (20% of Tex19.12/2 embryos die without
concurrent lactation, 66% die with concurrent lactation) and
that loss of Tex19.1 was affecting viability of female
embryos more strongly than male embryos specifically in the
concurrent pregnancies (Tex19.12/2 homozygotes born with
a 1:1 male:female sex ratio without concurrent lactation,
4.7:1 male:female sex ratio with concurrent lactation) (Supple-
mentary Material, Table S2). Concurrent lactation has been
reported to affect the viability of embryos in a sex-specific
manner in some mouse strains (38), and this phenomenon
appears to be exacerbating the Tex19.12/2 embryonic lethality
phenotype. Differences between breeding schedules, which
significantly influence the magnitude and sex-specificity of
the effects of Tex19.12/2 on embryonic lethality, are likely
to account for differences between the data in Supplementary
Material, Table S1 and previously published observations
(37). Therefore, we performed subsequent analyses on preg-
nancies where mothers were not concurrently lactating to
avoid this issue.
The reduced viability of Tex19.12/2 embryos could be indi-
cative of defects in placenta function. Therefore, we assessed
the size and weight of Tex19.12/2 placentas and embryos
during development. Tex19.12/2 embryos dissected at E18.5
appeared visibly smaller than their heterozygous and wild-type
littermates (Fig. 3A). We measured this effect by weighing
E18.5 embryos and observed a 20% reduction (P, 0.01,
Mann–Whitney U-test) in embryo weight in both male and
female Tex19.12/2 embryos (Fig. 3C). Tex19.12/2 placentas
are also smaller than wild-type and heterozygous littermates
at E18.5: female and male Tex19.12/2 placentas are 26%
(P , 0.01, Mann–Whitney U-test) and 30% (P, 0.01,
Mann–Whitney U-test) lighter than littermate controls, re-
spectively (Fig. 3A and D). Although Tex19.12/2 embryos
are smaller than their littermates during embryonic develop-
ment, male Tex19.12/2 animals reach normal weights
during post-natal growth (Fig. 3E). In contrast, adult female
Tex19.12/2 animals remain slightly smaller (8% reduction
in weight, Mann–Whitney U-test, P , 0.01) than their
littermate controls (Fig. 3B and E). However, the reduction
in Tex19.12/2 female weight is less severe in adults than in
embryos. Taken together, the reduction in placental weight
and intra-uterine growth defect present in Tex19.12/2
embryos suggest that Tex19.1 is required for normal placenta
function during development.
Tex19.12/2 placentas have defects in the junctional zone
and labyrinth
We next examined whether any defects in Tex19.12/2 placen-
tal function might be caused by abnormalities in placenta
structure or development. Histology of E18.5 placenta sections
revealed that Tex19.12/2 placentas possess the main structural
layers: decidua basalis, junctional zone and labyrinth
(Fig. 4A). However, the junctional zone appears to be
thinner in Tex19.12/2 placenta sections when compared
with littermate controls. To further investigate any potential
defects in the junctional zone, we used periodic-acid Shiff’s
(PAS) stain to label the carbohydrate-rich junctional zone
and decidua basalis layers (Fig. 4B) and measured the area
of the junctional zone relative to the total placenta area in sec-
tions (Fig. 4E). This confirmed that there is a 40% reduction
in the amount of junctional zone in Tex19.12/2 placentas rela-
tive to littermate controls (P, 0.05, t-test).
The junctional zone comprises two main cell types, spon-
giotrophoblasts and glycogen trophoblasts, each of which is
derived from the trophectoderm (34). To investigate whether
loss of Tex19.1 affects one or both of these cell types in the
junctional zone, we counted the number of glycogen tropho-
blasts and spongiotrophoblasts in histological sections of
E18.5 placentas (Fig. 4C and F). Interestingly, the abundance
of both spongiotrophoblasts and glycogen trophoblasts was
reduced by 40% (P , 0.05, t-test) and 80% (P , 0.05,
t-test), respectively in Tex19.12/2 placentas. Thus, the reduc-
tion in the thickness of the junctional zone in Tex19.12/2 pla-
centas is presumably caused by reduced numbers of
spongiotrophoblast and glycogen trophoblast cells in this
tissue.
In addition to the histological defects in the junctional zone
of Tex19.12/2 placentas, we also noticed a difference in the
labyrinth layer, which appeared to have fewer sinusoidal
trophoblast giant cells, another trophectoderm-derived cell
type (34), than their littermate controls (Fig. 4D). Cell
counts confirmed that this cell type is 40% (P, 0.05, t-test)
less abundant in Tex19.12/2 placentas (Fig. 4F). Thus, loss
of Tex19.1 affects trophectoderm-derived cells in both the
junctional zone and labyrinth of the placenta.
As loss of Tex19.1 appears to be affecting multiple cell
types in the placenta, we performed qRT-PCR for cell type
markers to confirm and extend our histological analysis. Tek,
a marker of extraembryonic mesoderm-derived endothelial
tissues (39), does not show any statistically significant
change in mRNA abundance in Tex19.12/2 placentas when
compared with littermate controls (Fig. 5A). Similarly,
mRNAs encoding markers of chorion-derived trophoblast
cells in the labyrinth (Dlx3, Nr6a1) (40), and markers of the
two syncytiotrophoblast layers (Syna and Synb) (40), do not
significantly change abundance in Tex19.12/2 placentas
either (Fig. 5A). However, mRNA for the sinusoidal
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trophoblast giant cell marker Ctsq (40) is significantly
depleted (4-fold, P, 0.05, t-test) in Tex19.12/2 placentas,
and levels of Hand1 mRNA, a marker for trophoblast giant
cells (40), were also reduced (2-fold, P , 0.05, t-test)
(Fig. 5A). This is consistent with our histology data showing
that Tex19.12/2 placentas have fewer sinusoidal trophoblast
giant cells. Similarly, 2-fold reductions (P , 0.05) in the
levels of junctional zone markers [Tpbpa, glycogen tropho-
blasts and spongiotrophoblasts (41); Pcdh12 and Gjb3, glyco-
gen trophoblasts (41,42); Prl8a8 and Prl3a1,
spongiotrophoblasts (41)] in Tex19.12/2 placentas are consist-
ent with the reduced thickness of this layer and the reduction
in the number of glycogen trophoblasts and spongiotropho-
blasts we observed histologically.
We performed a more objective analysis of gene expression
changes in Tex19.12/2 placentas using Illumina WG-6v2.0
Beadchip microarrays to profile gene expression at a genome-
wide level. Microarray analysis shows that mRNAs for only 2
genes increase in abundance by more than 3-fold in
Tex19.12/2 placentas (P , 0.01) and that mRNAs for 22
genes decrease in abundance by the same amount (P, 0.01)
(Fig. 5B). A number of placenta-associated gene families,
such as placental lactogen genes (Prl), pregnancy-specific
glycoprotein genes (Psg), cathepsin genes (Cts) and caudal
homeobox genes (Cdx) (41,43–45), had multiple genes
whose mRNAs were at least 1.5-fold lower in Tex19.12/2 pla-
centas (P , 0.05) [microarray data are available in GEO re-
pository (46) accession GSE41823]. Expression levels of
seven placental lactogen genes (Prl7c1, Prl4a1, Prl3c1,
Prl5a1, Prl7b1, Prl8a6 and Prl8a9), six pregnancy-specific
glycoprotein genes (Psg17, Psg18, Psg19, Psg23, Psg25 and
Psg29), three cathepsin genes (Ctsm, Cts3, Cts6) and two
caudal homeobox genes (Cdx1 and Cdx2) were all reduced
in the Tex19.12/2 placentas by these criteria. We verified by
qRT-PCR that mRNAs for candidate genes belonging
to each of these families are less abundant in Tex19.12/2 pla-
centas than littermate controls (P , 0.05, t-test) (Fig. 5C).
Taken together, the microarray and qRT-PCR data are con-
sistent with our histological analyses and show that the
amount of junctional zone in the placenta and the abundance
of specific trophoblast cell types are reduced in the absence
of Tex19.1.
Figure 3. Tex19.12/2 embryos have small placentas and intrauterine growth retardation. (A) Photograph of E18.5 embryos and their placentas in a single litter
from a cross between Tex19.1+/2 heterozygotes. The Tex19.1 genotype is indicated. Scale bar, 500 mm. (B) Photograph of 6–8 week old female adult mice. The
Tex19.1 genotype is indicated. (C–E) Boxplots showing the weights of littermate E18.5 embryos (C), E18.5 placentas (D) and adult animals (E) derived from
heterozygous crosses, grouped according to sex and Tex19.1 genotype. ∗ indicates P , 0.01 (Mann–Whitney U-test).
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A number of imprinted genes are important for placenta de-
velopment and function, and some imprinted genes have dif-
ferent requirements for their silencing in hypomethylated
placental tissue than in the embryo-derived somatic cells
(47,48). Defective silencing of the imprinted allele of imprinted
genes would result in a gene expression change that falls below
the 3-fold cutoff used in the microarray analysis in Figure 5B,
but these changes can be sufficient to cause a placenta phenotype
(49,50). However, even in the absence of a fold-change threshold,
imprinted genes are no more likely to be differentially expressed
in Tex19.12/2 placentas than non-imprinted genes (Supplemen-
tary Material, Fig. S2). Although we cannot exclude the possibil-
ity that differences in cell composition between Tex19.12/2 and
control placentas are masking the detection of derepression of
imprinted genes, loss of Tex19.1 does not appear to be causing
widespread defects in imprinted gene silencing in the placenta.
Figure 4. Tex19.12/2 placentas have reduced numbers of spongiotrophoblasts, glycogen trophoblasts and sinusoidal trophoblast giant cells. (A) Haematoxylin
and eosin staining of E18.5 Tex19.1+/+, Tex19.1+/2 and Tex19.12/2 placenta sections. The approximate positions of the decidua basalis (db), junctional zone
(Jz) and labyrinth (L) layers are indicated. Scale bar, 500 mm. (B) PAS staining of E18.5 placenta sections highlighting the carbohydrate-rich decidua basalis and
junctional zone layers in the placenta. Scale bar, 500 mm. (C and D) High magnification images of placenta sections stained with PAS and haematoxylin. Regions
of the junctional zone (C) and labyrinth (D) are shown. Scale bars, 50 mm. (E) Contribution of the junctional zone to the placenta in PAS-stained sections. Error
bars indicate standard error, ∗ indicates P , 0.05 (t-test). (F) Abundance of trophoblast cell types in Tex19.12/2 and control littermate placenta sections. n ¼ 3,
error bars indicate standard error, ∗ indicates P, 0.05 (t-test). spT, spongiotrophoblast; glyT, glycogen trophoblast; S-TGC, sinusoidal trophoblast giant cell.
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Tex19.12/2 placentas derepress retrotransposons
We have previously shown that Tex19.1 represses the LTR
retrotransposon MMERVK10C in spermatocytes (19).
However, any derepression of retrotransposon expression in
Tex19.12/2 placentas would not be detected in the gene ex-
pression microarray analysis as any retrotransposon probes
in the microarray were excluded from the gene expression
analysis. Therefore, we re-analyzed the Tex19.12/2 placenta
microarray data using our recently developed microarray
repeat-annotation technique (10) and found that a number of
microarray probes corresponding to the LINE and LTR
classes of retrotransposon are upregulated between 2- and
Figure 5. Tex19.12/2 placentas have altered mRNA levels reflecting reduced numbers of trophoblast cells. (A and C) qRT-PCR for selected markers of different
placental cell types (A) and gene families identified by microarray (C) in E18.5 Tex19.12/2 placentas. Expression relative to Tex19.1+/+ placentas is indicated.
n ¼ 6, error bars indicate standard error, ∗ indicates P, 0.05 (t-test). Endo, endothelial cell; Troph, trophoblast; S-TGC, sinusoidal trophoblast giant cell;
SynT-I, syncytial trophoblast type I; SynT-II, syncytial trophoblast type II, TGC, trophoblast giant cell; spT, spongiotrophoblast; glyT, glycogen trophoblast.
(B) Volcano plot of gene expression microarray data showing the probability that each gene on the microarray is differentially expressed and its level of
upregulation in Tex19.12/2 placentas. Genes changing more than 3-fold (P , 0.01) are highlighted in pink and annotated with their gene names.
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4-fold in Tex19.12/2 placentas relative to littermate controls.
Interestingly, 11 of the 13 retrotransposon probes that are
upregulated more than 2-fold in Tex19.12/2 placentas (P ,
0.01) correspond to LINE-1 elements (Fig. 6A), one of the
most abundant retrotransposons in the mouse genome (2).
An LTR retrotransposon probe corresponding to MMVL30
LTR retrotransposons is also among the upregulated retro-
transposon probes in Tex19.12/2 placentas (Fig. 6A).
The large number of significantly upregulated LINE-1
probes in the Tex19.12/2 placenta microarray data prompted
us to look more closely at LINE-1 expression in this tissue.
Overall, LINE-1 probes were differentially distributed relative
to non-repeat probes within the microarray dataset (Mann–
Whitney U-test, P , 0.01), and a subset of LINE-1 probes
showed a 2-fold upregulation in Tex19.12/2 placentas rela-
tive to littermate controls (Fig. 6B). However, some LINE-1
probes appear to be more strongly affected by loss of
Tex19.1 than others (Fig. 6B). We verified the microarray
repeat-annotation data by performing qRT-PCR on
Tex19.12/2 placentas and littermate controls. Consistent
with the microarray data, MMERVK10C and IAP retrotranspo-
sons are not upregulated in Tex19.12/2 placentas by qRT-PCR
(Fig. 6C); however, MMVL30 retrotransposons are modestly
upregulated 1.7-fold (t-test, P , 0.05). Generic primers to
the ORF2 region of LINE-1 and primers designed to detect
the copies of LINE-1 that correspond to the upregulated micro-
array probes, all show a modest but statistically significant
1.6–2-fold (P , 0.05) upregulation in Tex19.12/2 placentas
by qRT-PCR (Fig. 6C). We confirmed that the upregulation of
LINE-1 mRNA in Tex19.12/2 placentas that we detected by
microarray and qRT-PCR represents a bona fide increase in
LINE-1 element expression by western blotting for LINE-1
ORF1p (Fig. 6D). Tex19.12/2 placentas showed a modest,
but consistent increase in LINE-1 ORF1p protein abundance
commensurate with the 2-fold increase in LINE-1 mRNA
levels detected by qRT-PCR and microarray (Fig. 6D).
The increase in LINE-1 mRNA and protein abundance that
occurs in Tex19.12/2 placentas could be caused by the differ-
ence in cell composition between wild-type and knockout pla-
centas, or by upregulation of LINE-1 in the trophoblast cell
types that normally express Tex19.1. Immunohistochemistry
for LINE-1 ORF1p protein showed that LINE-1 is primarily
expressed in the junctional zone trophoblast cells in both
Tex19.12/2 and control littermate placentas, with some low
level expression also detectable in the trophoblast giant cells
in the labyrinth (Fig. 6E). The cell types primarily expressing
LINE-1 in Tex19.12/2 placentas are, therefore, the
trophectoderm-derived cell types that normally express
Tex19.1. Furthermore, as there are fewer junctional zone
trophoblast cells in Tex19.12/2 placentas (Fig. 4), the
2-fold increases in LINE-1 expression observed by
qRT-PCR and western blotting likely underestimate the in-
crease in LINE-1 expression that occurs in the junctional
zone cells that remain in Tex19.12/2 placentas (Fig. 6D and
E). Taken together, these data suggest that expression of the
genome-defence gene Tex19.1 is linked to the epigenetic
state of the placenta and suppresses LINE-1 retrotransposons
in the hypomethylated trophectoderm-derived cells in this
tissue.
DISCUSSION
Suppressing retrotransposons in the hypomethylated
placenta
The mammalian placenta has been associated with retrotrans-
poson expression in a number of studies (reviewed in 29), and
retrotransposon-derived proteins have even been co-opted to
fulfil placental functions on multiple occasions during mam-
malian evolution (51–54). However, our microarray analysis
of retrotransposon expression suggests that, although a
number of retrotransposons are differentially expressed
between placenta and embryo, the murine placenta is in
general no more permissive for retrotransposon expression
than the rest of the embryo. This contrasts strongly with, for
example, ES cells knocked down for the histone methyltrans-
ferase Eset that show widespread upregulation of many differ-
ent types of retrotransposon in microarray repeat annotation
(10). Studies assessing the behaviour of specific types of retro-
transposons in the human placenta also suggest that the asso-
ciation between retrotransposon expression and the placenta
reflects expression of a subset of hypomethylated genomic
copies of these elements (55). Thus, the strong associations
between retrotransposon expression and the placenta might
represent expression of specific types of retrotransposon, or
even expression of specific genomic copies of a retrotrans-
poson, rather than a widespread general activation of retro-
transposon expression in this tissue.
Multiple retrotransposon families and classes have been
reported to be DNA hypomethylated in the placenta relative
to the embryo (25,27,28). At least for LINE-1, this hypomethy-
lation is present in trophectoderm-derived rather than extraem-
bryonic mesoderm-derived components of the placenta (25).
IAP elements appear to be repressed by DNA methylation in
multiple embryo-derived cell types (11,30,31) and is one of
the hypomethylation-sensitive genes strongly activated in
mouse somatic cells in multiple models of DNA hypomethyla-
tion (17). Thus, although the hypomethylated state of the pla-
centa does not appear to cause widespread derepression of
retrotransposons in general, the derepression of IAP elements
in the placenta likely represents a direct consequence of its
hypomethylated state. A number of other retrotransposons
that have been shown to be repressed by DNA methylation
in ES cells or germ cells, including LINE-1 (9,10,33), do not
appear to be strongly upregulated in the placenta relative to
the embryo. However, it is still the hypomethylated derivatives
of the trophectoderm that are the primary source of LINE-1
ORF1p expression in this tissue. Thus, although differences
in transcription factor expression, and/or differences in add-
itional retrotransposon suppression mechanisms, could all con-
tribute to the differential sensitivity of retrotransposons to
DNA hypomethylation between placenta and embryo, the
hypomethylated epigenetic state of the trophectoderm deriva-
tives within the placenta does appear to make these cell types
vulnerable to retrotransposon activity.
We have recently shown that the DNA hypomethylation
that occurs in developing primordial germ cells induces ex-
pression of a cohort of germline genome-defence genes that
can act to protect the genome from the activity of any retro-
transposons that might be derepressed during this period of
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epigenetic reprogramming (17). Interestingly, although this
cohort of genes all become hypomethylated and expressed
during the extensive epigenetic reprogramming event that
occurs in the developing germline, only Tex19.1 is hypo-
methylated and expressed in the placenta. DNA hypomethyla-
tion in developing germ cells has been proposed to occur
through multiple active mechanisms (27,56), whereas DNA
hypomethylation in the placenta might be a consequence of
reduced de novo DNA methylation in trophectoderm-derived
cells (57,58), possibly in combination with additional events.
Differences between the molecular mechanisms responsible
for DNA hypomethylation could potentially account for the
differences in genome-defence gene promoter methylation
between the placenta and the germline. However, our finding
that Tex19.1 functions to repress retrotransposons in the pla-
centa, where the remaining genome-defence genes are not
expressed, suggests that at least some genome-defence genes
are able to function independently of each other, possibly in
a modular manner. Deploying a group of genome-defence
genes in hypomethylated germ cells that are each independent-
ly able to target multiple retrotransposons at different stages of
the retrotransposon life cycle would be expected to provide an
effective multi-layered defence against these elements.
Tex19.1 function in the placenta
Our study shows that Tex19.1 is required for normal
placenta development and function. In the absence of
Tex19.1, trophectoderm-derived spongiotrophoblasts, glyco-
gen trophoblasts and sinusoidal trophoblast giant cells are all
reduced in abundance, or have altered gene expression pat-
terns in the placenta. TEX19.1 protein is expressed in the
trophoblast giant cells, extraembryonic ectoderm and chorion
at E6.5 and E7.5 (17), and the defects that we describe here
Figure 6. LINE-1 retrotransposons are de-repressed in Tex19.12/2 placentas. (A) Bar chart showing all retrotransposon probes that change expression more than
2-fold (P , 0.01) in Tex19.12/2 placentas. (B) Probability density function plots showing the relative likelihood that the microarray signal of any individual
LINE-1 probe is increased by the indicated amount in Tex19.12/2 placentas. Dotted lines mark 2-fold changes in expression. (C) qRT-PCR analysis of expres-
sion of selected retrotransposons in Tex19.12/2 placentas at E18.5. Error bars represent standard error, n ¼ 6, asterisks indicate P , 0.05 (t-test). (D) Western
blot for LINE-1 ORF1p, TEX19.1 and b-actin in Tex19.1+/+ and Tex19.12/2 placentas. (E) Immunohistochemistry (brown precipitate) for LINE-1 ORF1p in
E18.5 Tex19.1+/+ and Tex19.12/2 placentas. Sections are counterstained with haematoxylin. Approximate positions of the decidua basalis (db), junctional zone
(Jz) and labyrinth (L) are indicated. No specific staining was detected with non-specific IgG controls. Scale bar, 200 mm.
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in E18.5 placenta may arise from defects at much earlier
stages of placenta development. We have previously shown
that Tex19.1 plays a role in suppressing a specific LTR retro-
transposon, MMERVK10C, in the developing germline, but
has no effect on the abundance of LINE-1 mRNA in that
tissue (10,19). Our findings here extend the range of retrotran-
sposons that this genome-defence mechanism is targeting and
highlight the complex interplay that is operating between
genome-defence mechanisms in different tissues. The insensi-
tivity of LINE-1 to the loss of Tex19.1 in developing germ
cells presumably reflects the existence of multiple overlapping
defence mechanisms operating against this element in the
germline. Analysis of retrotransposon mRNAs might be a rela-
tively indirect approach to detect the activity of Tex19.1, and
the increases in retrotransposon mRNA that we have identified
in the placenta (this study) and in the testis (19) could reflect
loss of a genome-defence mechanism operating at any point in
a retrotransposon life cycle as increased flux through a retro-
transposon life cycle will generate an increase in the
genomic copy number of that element that can then produce
more retrotransposon mRNA. Differences in the types of retro-
transposon derepressed in Tex19.12/2 testes and Tex19.12/2
placentas may simply reflect the presence or absence of
mechanisms that are operating alongside Tex19.1 to suppress
different retrotransposons at different stages of their life
cycle in each of these tissues.
The increase in LINE-1 retrotransposon mRNA that is
present in Tex19.12/2 placentas has the potential to cause
increased retrotransposition and could also reflect increased
LINE-1 retrotransposition that has already occurred in this
tissue. Emerging technologies that identify and map de novo
LINE-1 retrotransposition events in human tissue (59,60)
might allow the extent of any de novo LINE-1 retrotransposi-
tion in these mouse tissues to be assessed in future studies. As
Tex19.1 is expressed from early stages of placental develop-
ment, there is plenty of opportunity for any increased
LINE-1 expression in these mutant tissues to cause de novo
retrotransposition and for these de novo retrotransposition
events to accumulate and cause genetic instability. We have
not yet determined whether the reduction in placental cell
types and changes in mRNA abundance that we describe in
Tex19.12/2 placentas are caused by increased apoptosis,
decreased proliferation or impaired differentiation. In addition,
although Tex19.1 has a role in suppressing retrotransposons in
the placenta, we cannot exclude the possibility that Tex19.1
also has a role in mediating other aspects of cell function
and that the placental defects in Tex19.12/2 mice are not dir-
ectly caused by an increase in retrotransposition. However, it
is also possible that the defects that we observe in
Tex19.12/2 placentas are a direct consequence of increased
retrotransposon activity causing high levels of insertional mu-
tagenesis. As some combinations of de novo LINE-1 integra-
tion events are likely to be more deleterious than others, the
somatic variation between cells in Tex19.12/2 placentas
could result in sporadic occurrences of cell death, proliferation
defects or developmental abnormality in trophectoderm-
derived cell types throughout placenta development. LINE-1
retrotransposition has been proposed to generate somatic vari-
ation in human neural tissue (61) and to drive tumourigenesis
in some cases of human colorectal cancer (60). Thus, although
a small amount of LINE-1 retrotransposition has been pro-
posed to be important for generating somatic variation and
normal brain function, too much retrotransposition is likely
to be deleterious. It would appear that mutating Tex19.1
might be sufficient to this balance in the developing placenta.
The exacerbating sex-biased effect that concurrent lactation
has on Tex19.12/2 embryonic lethality is intriguing, but the
molecular basis for this phenomenon is not clear at present.
The preferential loss of XX Tex19.12/2 embryos during con-
current lactation could indicate defects in X-inactivation under
these conditions. However, the Tex19.12/2 placental pheno-
type that we describe in this work occurs in both XX and
XY placentas suggesting that Tex19.1 is not required for
X-inactivation in the absence of concurrent lactation and
that X-inactivation defects are not causing the placental
phenotype characterized here. In addition, there is no evidence
for activation of X-linked genes in the microarray gene expres-
sion profiles of XX Tex19.12/2 placentas (Supplementary Ma-
terial, Fig. S3). Interestingly, there are differences in gene
expression between XX and XY placentas, and gene expres-
sion in XX placentas is more sensitive to changes in maternal
diet than gene expression in XY placentas (62,63). Perhaps the
increased nutritional demand of concurrent pregnancy and lac-
tation is similarly altering placenta gene expression, and these
changes could be increasing the requirement for Tex19.1 func-
tion in this tissue. Given the findings presented here, it would
be of interest to determine whether retrotransposon expression
or activity is altered in the placenta during concurrent lactation
and pregnancy.
Although placenta development is compromised in the
absence of Tex19.1, Tex19.1 does not appear to be absolutely
required for development or survival of any specific terminally
differentiated placenta cell type. Nevertheless, Tex19.12/2
embryos exhibit intra-uterine growth retardation suggesting
that loss of Tex19.1 impairs placenta function. The reduction
in the number of trophoblast cells in Tex19.12/2 placentas
is likely to result in lower amounts of some placenta-derived
hormones entering the maternal circulatory system and
reduced communication across the maternal–fetal interface.
mRNAs encoding a number of secreted hormones such as pla-
cental lactogens, which are secreted into the maternal blood to
influence maternal metabolism (41), and pregnancy-specific
glycoproteins, one of the most abundant group of fetal-derived
proteins present in the maternal blood during pregnancy (44),
are all reduced in abundance in Tex19.12/2 placentas.
Pregnancy-specific glycoproteins have been proposed to
have a role in modulating maternal immune responses
during pregnancy, possibly through inducing expression of
anti-inflammatory cytokines (44). It is, therefore, noteworthy
that the two genes whose mRNAs were more than 3-fold
higher in Tex19.12/2 placentas, Npy and Ceacam1, have
been reported to be upregulated in response to inflammation
and to promote angiogenesis (64,65). Reduced levels of pla-
cental lactogens and pregnancy-specific glycoproteins in the
maternal blood have both been reported to be associated
with impaired placenta function and conditions such as intra-
uterine growth retardation and pre-eclampsia in humans (66).
The placental defects in Tex19.12/2 mice, therefore, raise the
intriguing possibility that deregulation of retrotransposons
could contribute to impaired placenta function in humans. In
1802 Human Molecular Genetics, 2013, Vol. 22, No. 9
 by guest on July 10, 2013
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
this respect, the generally hypomethylated epigenetic state of
the placenta might make retrotransposons in this tissue par-
ticularly sensitive to any additional epigenetic disruption or
sequence variation that would remove another layer of sup-
pression from these elements. Although there are a number
of differences between the retrotransposons present in
human and mouse genomes (1,2), and presumably also
between genome-defence mechanisms operating between
these species, it is possible that imbalances between retrotrans-
poson suppression and genome-defence mechanisms might
contribute to placenta dysfunction and disease in both mice
and humans.
MATERIALS AND METHODS
Animals
The Tex19.1 mutation used in this study is a complete replace-
ment of the Tex19.1 open reading frame (19), back-crossed
three times to C57BL/6 mice (Charles River). For timed
matings, noon on the day the vaginal plug was found was
termed E0.5. Genotyping was performed essentially as
described (19). All animal experiments were performed in
concordance with local ethical guidelines and national regula-
tions under the authority of UK Home Office Project Licence
PPL 60/3785.
qRT-PCR
RNA was extracted from tissues using TRIzol (Invitrogen),
DNAse-treated and used as a template for random-primed
cDNA synthesis with Superscript III (Invitrogen). Quantitative
PCR was performed using this cDNA as a template, primers
listed in Supplementary Material, Table S3, Brilliant II
SYBR Green QPCR Master Mix (Agilent Technologies) and
a CFX96 Real-Time PCR Detection System (Bio-Rad). Quan-
tification was performed relative to a standard curve, and
b-actin was used to normalize gene expression between
samples. Data were tested for statistical significance using a
two-tailed t-test. Six Tex19.12/2 placentas and six
Tex19.1+/2 or Tex19.1+/+ control littermate placentas were
used for qRT-PCR assays to investigate changes in mRNA
abundance in Tex19.12/2 placentas (four XX and two XY
for each group).
Bisulphite sequencing
Genomic DNA was extracted from tissues by SDS/proteinase
K lysis and ethanol precipitation. Five hundred nanograms of
genomic DNA were bisulphite treated with the EZ DNA
Methylation Gold kit (Zymo Research), then used as a tem-
plate for nested PCR using primers listed in Supplementary
Material, Table S3. PCR products were gel purified using a
Nucleospin Extract II kit (Macherey-Nagel) and cloned into
pGEM-T Easy (Promega). Plasmid DNA from individual col-
onies was isolated, sequenced using the SP6 sequencing
primer, and the methylation status of each CpG in the
plasmid insert was determined and plotted using QUMA
(67). Sequences were excluded from the analysis, if the CpH
conversion rate was less than 95%, or if identical sequences
were already present in the sample.
Microarray
RNA was isolated from six Tex19.12/2 and six Tex19.1+/2 or
Tex19.1+/+ control littermate placentas (four XX and two XY
for each group) using TRIzol (Invitrogen) and biotin-labelled
using the Illumina TotalPrep RNA Amplification Kit
(Ambion). RNA quality was assessed using an Agilent Bioa-
nalyzer (RNA Integrity Number ≥8) and labelled RNA hybri-
dized to Illumina Mouse WG-6 v2.0 Expression Beadchips.
For analysis of gene expression in this dataset, the raw
sample probe and control probe data from Illumina Beadstudio
were read into R (68), background-adjusted (force Positive
method), log-transformed and quantile-normalized using
lumi (69). Poorly performing probes were removed from the
dataset as described (70), and probe level data summarized
to gene level using limma. Differences between Tex19.12/2
and control littermate datasets were identified by linear mod-
elling with limma (71), using false discovery rate-adjusted
P-values to determine statistical significance. The
Tex19.12/2 placenta microarray data are available in the
GEO repository (46), accession GSE41823. Gene expression
analysis of publicly available multiple-tissue microarray data
(32) (GEO accession GSE9954) was performed similarly,
except that the rma method in affy (72) rather than lumi was
used for pre-processing. Probe level repeat-annotation of
microarray data (GEO accessions GSE9954 and GSE41823)
was performed as previously described (10).
Histology and immunohistochemistry
Tissue was fixed with freshly depolymerized 4% paraformal-
dehyde in PBS at 48C overnight, washed with PBS, then dehy-
drated through ethanol, xylene and embedded in paraffin wax.
Microtome sections (6 mm) were collected on glass slides,
dewaxed with xylene and re-hydrated through ethanol to
dH2O. For histology, sections were then stained with either
haematoxylin and eosin, PAS or PAS and haematoxylin. For
immunohistochemistry, antigen retrieval was performed by
boiling the slides in 0.1 M citrate buffer pH 6.0 in a microwave
for 15–20 min. Sections were treated with 3% H2O2 in metha-
nol for 30 min, blocked with PBS containing 10% goat serum
and 0.1% Tween, then incubated with primary antibodies
[rabbit anti-Tex19.1 (19), 1:300; rabbit anti-IAP gag, 1:300
(73); rabbit anti-LINE-1 ORF1p, 1:500 (74)] diluted in block-
ing buffer at 48C overnight. Sections were washed with PBS,
bound primary antibody was detected using the Envision HRP
Rabbit DAB+ system (Dako) and sections were counter-
stained with haematoxylin. Stained sections were dehydrated
through ethanol and xylene, mounted with DPX mounting
media (CellPath) and photographed using an Olympus BX51
upright or Zeiss Axioplan 2 microscope equipped with a
digital camera.
For measurement of the contribution of junctional zone to
the placenta, shapes were drawn around the junctional zone
and the entire placenta on digital images of PAS-stained sec-
tions for each placenta, and areas calculated using the
Olympus dotSlide system. For measurement of cell type
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abundance, three separate rectangular segments were drawn on
digital images of PAS and haematoxylin-stained sections of
each placenta, with each segment spanning the entire width
of the placenta section. The numbers of spongiotrophoblast,
glycogen trophoblast and sinusoidal trophoblast cells in each
segment were counted, and the area of the placenta within
each segment was calculated using the Olympus dotSlide
system.
Western blotting
Placenta was homogenized in Laemmli sample buffer (60 mM
Tris pH 6.8, 2% SDS, 10% glycerol, 0.1 M dithiothreitol and
0.01% bromophenol blue), boiled for 5 min and then sonicated
to disrupt genomic DNA. Western blotting was performed
using an Invitrogen precast gel system according to the man-
ufacturer’s instructions. Rabbit anti-TEX19.1 polyclonal anti-
bodies (19) were used at a 1:100 dilution, mouse anti-b-actin
antibodies (Abcam) at 1:5000 and rabbit anti-LINE-1 ORF1p
(74) at 1:2000. Bound primary antibodies were detected with
peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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